Expanding Ortivus’ product range with new applications.
Significant events for the period April – June 2023
- Ortivus is awarded a contract for the delivery of equipment to the ambulance and hospital operations of Region Kronoberg. The contract pertains to the delivery of Ortivus’ solution MobiMed Life, semi-automatic and manual defibrillators. The order value is estimated to be 4.9 MSEK, and the contract duration is 2 years with a potential extension of 1+1 years.
- Ortivus qualifies for the NHS framework agreement concerning MobiMed Life, creating new opportunities in the United Kingdom.
- Ortivus’ product range is further expanded through an asset acquisition of the vehicle control system FleetCtrl, which, together with Ortivus’ other solutions, constitutes a competitive total solution for the future of healthcare.
Significant events after end of the period
- Ortivus has entered into a contract to supply MobiMed ePR and MobiMed enRoute to support the ambulance operations of Region Jönköpings län. The contract duration is 5 years, with the possibility of an extension for another 5 years. The order value amounts to 4.2 MSEK during the initial contract period, and an additional 4.2 MSEK in the event of a contract extension.
- A subcontractor responsible for the data operation of MobiMed ePR falls victim to a criminal cyberattack, affecting some of the company’s British clients. The system is isolated, and the application becomes unavailable for a period of time.
- Ortivus enters into an agreement with the company’s main shareholder, Ponderus Invest, covering a credit line of 8.0 MSEK. The company’s liquidity is being strengthened to effectively manage prolonged procurement processes, delayed deliveries, and customer payments.
April – June 2023
- Net sales amounted to 20.7 (26.4) MSEK.
- The gross margin amounted to 37% (57%).
- EBITDA amounted to -4.8 (3.5) MSEK.
- Earnings after tax per share before and after dilution amounted to -0.11 (0.08) SEK.
- Operating cash flow before changes in working capital amounted to -4.3 (8.9) MSEK.
January – June 2023
- Net sales amounted to 48.7 (51.0) MSEK.
- The gross margin amounted to 43% (53%).
- EBITDA amounted to -4.6 (5.5) MSEK.
- Earnings after tax per share before and after dilution amounted to -0.10 (0.12) SEK.
- Operating cash flow before changes in working capital amounted to -2.8 (0.8) MSEK.
| Apr-Jun 2023 | Apr-Jun 2022 | Jan-Jun 2023 | Jan-Jun 2022 | Jan-Dec 2022 | |
| Net sales (MSEK) | 20.7 | 26.4 | 48.7 | 51.0 | 104.5 |
| Gross margin (%) | 37% | 57% | 43% | 53% | 47% |
| Operating profit (MSEK) | -4.7 | 3.5 | -4.2 | 5.5 | 5.8 |
| Operating margin (%) | -23% | 13% | -9% | 11% | 6% |
| EBITDA (MSEK) | -3.5 | 4.4 | -2.0 | 6.8 | 10.2 |